Beta Bionics taps Senseonics’ implantable glucose monitor for artificial pancreas

Share

Beta BionicsSenseonics‘ (NYSE:SENS) said today that it inked a deal to integrate glucose data from its Eversense continuous glucose monitoring system into Beta Bionics‘ investigational iLet bionic pancreas.

According to the terms of the development agreement, Beta Bionics and Senseonics will work together to combine the two systems in the hopes of driving insulin and glucagon dosing with real-time data from the Eversense monitor.

Get the full story at our sister site, Drug Delivery Business News.

 

Don't Miss the Most Anticipated Conference of the Fall!

textadimage DeviceTalks Boston is just a few months away. More than 50 speakers and 35 exhibitors will join over 400 members of this red-hot industry, for a look inside the most important developments facing our community.

Join us for three days of world-class education, networking, and a technology exhibition featuring the leading companies in the industry.

Take a look at our speaker line-up and more.

Speak Your Mind

*